Form 4: VolitionRx CEO's Tax Withholding on RSU Vesting

VolitionRx's CEO of Volition Veterinary, Salvatore Thomas Butera, had 5,834 shares withheld by the company to cover tax obligations related to the vesting of 21,333 restricted stock units.

Summary

• Salvatore Thomas Butera, CEO of Volition Veterinary, reported a transaction on October 4, 2025.
• 5,834 shares of VolitionRx common stock were withheld by the company.
• This withholding was to satisfy tax obligations arising from the settlement of 21,333 restricted stock units (RSUs).
• The shares were valued at $0.648 per share for this transaction.
• No shares were sold by the reporting person or VolitionRx in this transaction.
• Following this transaction, Butera directly owns 326,451 shares of common stock.
• Additionally, Butera jointly owns 99,350 shares of common stock with his spouse.

Sentiment

Score: 7

Explanation: The filing indicates the vesting of restricted stock units for a key executive, which is a positive sign of executive compensation realization and retention. The transaction itself is a routine tax withholding, not a sale, thus having a neutral to slightly positive impact on market sentiment.

Positives

• Vesting of 21,333 restricted stock units for CEO Salvatore Thomas Butera, indicating compensation realization and executive retention.
• The transaction was a tax withholding, not a sale of shares by the executive or the company, suggesting no direct market selling pressure from this event.

Negatives

• No direct negatives identified as this is a routine tax withholding event related to executive compensation.

Risks

• NA

Future Outlook

NA

Industry Context

This Form 4 details a routine executive compensation event, specifically the tax withholding associated with restricted stock unit vesting. Such events are common across publicly traded companies as part of their executive incentive and retention programs. It does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: Minimal direct impact as it is a routine tax withholding, not a market sale. It indicates executive compensation is being realized, which can be viewed as a positive for executive retention.
• Employees: May signal stability in executive compensation practices within the company.

Key Dates

Recommendation

This Form 4 details a routine executive compensation event (RSU vesting and tax withholding) and does not provide new information that would fundamentally alter the investment thesis for VolitionRx. It confirms an executive's continued stake in the company but offers no insights into operational performance, strategic shifts, or future prospects that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

VNRX, VolitionRx, Form 4, insider transaction, RSU, restricted stock units, executive compensation, Salvatore Thomas Butera, CEO, tax withholding